Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.
1. A heterodimeric bispecific antibody, comprising a first antigen-binding functional region capable of specifically binding to PD-L1 and a second antigen-binding functional region capable of specifically binding to PD-1, wherein the bispecific antibody comprises a first Fc chain and a second Fc chain linked by one or more interchain disulfide bonds, the first Fc chain and the second Fc chain being linked respectively to the PD-L1 antigen-binding functional region and the PD-1 antigen-binding functional region by a covalent bond or a linker; or the first Fc chain and the second Fc chain being linked respectively to the PD-1 antigen-binding functional region and the PD-L1 antigen-binding functional region by a covalent bond or a linker; and the first Fc chain and the second Fc chain comprise 5 amino acid substitutions at the following positions:
the amino acid substitutions on the first Fc chain are T366L and D399R, the amino acid substitutions on the second Fc chain are L351E, Y407L and K409V;
wherein the amino acid positions are numbered according to the Kabat EU index numbering system; and
wherein the PD-L1 antigen-binding functional region comprises the amino acid sequences set forth in SEQ ID NOs: 2 and 6; and the PD-1 antigen-binding functional region comprises the amino acid sequences set forth in SEQ ID NOs: 16 and 18.
2. The heterodimeric bispecific antibody according to claim 1 , wherein the Fc chains are derived from IgG.
3. The heterodimeric bispecific antibody according to claim 1 , wherein the PD-L1 and PD-1 antigen-binding functional regions are Fab fragments or scFv fragments.
4. The heterodimeric bispecific antibody according to claim 1 , wherein the PD-L1 and PD-1 antigen-binding functional regions are both Fab fragments.
5. The heterodimeric bispecific antibody according to claim 1 , wherein one of the PD-L1 and PD-1 antigen-binding functional regions is Fab fragment, and the other is scFv.
6. The heterodimeric bispecific antibody according to claim 1 , wherein the first Fc chain and the PD-L1 antigen-binding functional region linked thereto and the second Fc chain and the PD-1 antigen-binding functional region linked thereto, or the first Fc chain and the PD-1 antigen-binding functional region linked thereto and the second Fc chain and the PD-L1 antigen-binding functional region linked thereto, when present alone in the presence of a reducing agent, form homodimers at a ratio of less than 50% by weight.
7. The heterodimeric bispecific antibody according to claim 6 , wherein the first Fc chain and the PD-L1 antigen-binding functional region linked thereto comprises the amino acid sequences set forth in SEQ ID NOs: 2, 4, 6 and 8; the second Fc chain and the PD-1 antigen-binding functional region linked thereto comprises the amino acid sequences set forth in SEQ ID NOs: 4, 14, 16, and 18.
8. A composition comprising the heterodimeric bispecific antibody according to claim 1 and a pharmaceutically acceptable carrier.